Inhibition of connective tissue growth factor overexpression decreases growth of hepatocellular carcinoma cells in vitro and in vivo

Chinese Medical Journal

Volumn 124, Issue 22, 2011, Pages 3794-3799

  Jia, Xiao Qin ^a,b   Cheng, Hai Qing ^b   Li, Hong ^b   Zhu, Yan ^b   Li, Yu Hua ^b   Feng, Zhen Qing ^b   Zhang, Jian Ping ^c  

^a YANGZHOU UNIVERSITY   (China)

^b NANJING MEDICAL UNIVERSITY   (China)

^c THE SECOND AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Cell proliferation; Connective tissue growth factor; Hepatocellular carcinoma; siRNA

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; CONNECTIVE TISSUE GROWTH FACTOR; LENTIVIRUS VECTOR; MESSENGER RNA; SHORT HAIRPIN RNA; SMALL INTERFERING RNA;

ANALYSIS OF VARIANCE; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CANCER THERAPY; CANCER TISSUE; CARCINOMA CELL; CELL GROWTH; CELL LINE; CELL PROLIFERATION; CELL STRAIN HEPG2; CELL STRAIN LO2; CELL STRAIN MHCC 97H; CELL STRAIN SMMC 7721; CLONOGENESIS; COLONY FORMATION; CONTROLLED STUDY; DOWN REGULATION; GENE CONSTRUCT; GENE EXPRESSION; GENE OVEREXPRESSION; GENE SILENCING; GENE VECTOR; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL CARCINOMA; MALE; MOUSE; NONHUMAN; NUDE MOUSE; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; STATISTICAL SIGNIFICANCE; STUDENT T TEST; TUMOR CELL; TUMOR VOLUME; WESTERN BLOTTING; XENOTRANSPLANTATION;

ANIMALS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL PROLIFERATION; CONNECTIVE TISSUE GROWTH FACTOR; GENE EXPRESSION REGULATION, NEOPLASTIC; HEP G2 CELLS; HUMANS; LIVER NEOPLASMS; MALE; MICE; MICE, NUDE; RNA, SMALL INTERFERING; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 82255195473     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.2011.22.034     Document Type: Article

References (34)

1. Spangenberg HC, Thimme R, Blum HE. Evolving therapies in the treatment of hepatocellularcarcinoma. Biologics 2008; 2: 453-462.
2. Treiber G. Systemic treatment of hepatocellular carcinoma. Dig Dis 2001; 19: 311-323.
3. Spangenberg HC, Thimme R, Blum HE. Targeted therapy for hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol 2009; 6: 423-432.
4. Pang RW, Poon RT. From molecular biology to targeted therapies for hepatocellular carcinomacarcinoma: the future is now. Oncology 2007; 72 Suppl 1: 30-44.
5. You L, Chen G, Zhao YP. Core signaling pathways and new therapeutic targets in pancreatic cancer. Chin Med J 2010; 123: 1210-1215.
6. Liu YF, Zha BS, Zhang HL, Zhu XJ, Li YH, Zhu J, et al. Characteristic gene expression profiles in the progression from liver cirrhosis to carcinoma induced by diethylnitrosamine in a rat model. J Exp Clin Cancer Res 2009; 28: 107-123.
7. Qi W, Twigg S, Chen X, Polhill TS, Poronnik P, Gilbert RE, et al. Intergrated actions of transforming growth factor-batal and connective tissue growth factor in renal fibrosis. Am J Physio Renal Physiol 2005; 288: F800-F809.
8. Leask A, Abraham DJ. All in the CCN family: essential matricellular signaling modulators emerge from the bunker. J Cell Sci 2006; 119: 4803-4810.
9. Croci S, Landuzzi L, Astolfi A, Nicoletti G, Rosolen A, Sartori F, et al. Inhibition of connective tissue growth factor (CTGF/CCN2) expression decreases the survival and myogenic differentiation of human rhabdomyosarcoma cells. Cancer Res 2004; 64: 1730-1736.
10. Xie D, Nakachi K, Wang H, Elashoff R, Koeffler HP. Elevated levels of connective tissue growth factor, WISP-1, and CYR61 in primary breast cancers associated with more advanced features. Cancer Res 2001; 61: 8917-8923.
11. Pan LH, Beppu T, Kurose A, Yamauchi K, Sugawara A, Suzuki M, et al. Neoplastic cells and proliferating endothelial cells express connective tissue growth factor (CTGF) in glioblastoma. Neurol Res 2002; 24: 677-683.
12. Xie D, Yin D, Wang HJ, Liu GT, Elashoff R, Black K, et al. Levels of expression of CYR61 and CTGF are prognostic for tumor progression and survival of individuals with gliomas. Clin Cancer Res 2004; 10: 2072-2081.
13. Koliopanos A, Friess H, di Mola FF, Tang WH, Kubulus D, Brigstock D, et al. Connective tissue growth factor gene expression alters tumor progression in esophageal cancer. World J Surg 2002; 26: 420-427.
14. Shakunaga T, Ozaki T, Ohara N, Asaumi K, Doi T, Nishida K, et al. Expression of connective tissue growth factor in cartilaginous tumors. Cancer 2000; 89: 1466-1473.
15. Liu L, Li Z, Feng G, You W, Li J. Expression of connective tissue growth factor is in agreement with the expression of VEGF, VEGF-C,-D and associated with shorter survival in gastric cancer. Pathol Int 2007; 57: 712-718.
16. Sala-Torra O, Gundacker HM, Stirewalt DL, Ladne PA, Pogosova-Agadjanyan EL, Slovak ML, et al. Connective tissue growth factor (CTGF) expression and outcome in adult patients with acute lymphoblastic leukemia. Blood 2007; 109: 3080-3083.
17. Wong YF, Cheung TH, Tsao GS, Lo KW, Yim SF, Wang VW, et al. Genome-wide gene expression profiling of cervical cancer in Hong Kong women by oligonucleotide microarray. Int J Cancer 2006; 118: 2461-2469.
18. Deng YZ, Chen PP, Wang Y, Yin D, Koeffler HP, Li B, et al. Connective tissue growth factor is overexpressed in esophageal squamous cell carcinoma and promotes tumorigenicity through beta-catenin-T-cell factor/Lef signaling. J Biol Chem 2007; 282: 36571-36581.
19. Zirn B, Hartmann O, Samans B, Krause M, Wittmann S, Mertens F, et al. Expression profiling of Wilms tumors reveals new candidate genes for different clinical parameters. Int J Cancer 2006; 118: 1954-1962.
20. Chen PP, Li WJ, Wang Y, Zhao S, Li DY, Feng LY, et al. Expression of Cyr61, CTGF, and WISP-1 correlates with clinical features of lung cancer. PLoS One 2007; 2: e534.
21. Dornhöfer N, Spong S, Bennewith K, Salim A, Klaus S, Kambham N, et al. Connective tissue growth factor-specific monoclonal antibody therapy inhibits pancreatic tumor growth and metastasis. Cancer Res 2006; 66: 5816-5827.
22. Gressner OA, Gressner AM. Connective tissue growth factor: a fibrogenic master switch in fibrotic liver diseases. Liver Int 2008; 28: 1065-1079.
23. Kovalenko E, Tacke F, Gressner OA, Zimmermann HW, Lahme B, Janetzko A, et al. Validation of connective tissue growth factor (CTGF/CCN2) and its gene polymorphisms as noninvasive biomarkers for the assessment of liver fibrosis. J Viral Hepat 2009; 16: 612-620.
24. McManus MT, Sharp PA. Gene silencing in mammals by small interfering RNAs. Nat Rev Genet 2002; 3: 737-747.
25. Ke S, Chen XH, Zhu ZG, Li JF, Yu BQ, Gu QL, et al. Silencing invariant chains of dendritic cells enhances anti-tumor immunity using small-interfering RNA. Chin Med J 2010; 123: 3193-3199.
26. Duxbury MS, Whang EE. RNA interference: a practical approach. J Surg Res 2004; 117: 339-344.
27. Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 2001; 411: 494-498.
28. Sui G, Soohoo C, Affarel B, Gay F, Shi Y, Forrester WC, et al. A DNA vector-based RNAi technology to suppress gene expression in mammalian cells. Proc Natl Acad Sci U S A 2002; 99: 5515-5520.
29. Stewart SA, Dykxhoorn DM, Palliser D, Mizuno H, Yu EY, An DS, et al. Lentivirus-delivered stable gene silencing by RNAi in primary cells. RNA 2003; 9: 493-501.
30. Scherr M, Eder M. Gene silencing by small regulatory RNAs in mammalian cells. Cell Cycle 2007; 6: 444-449.
31. Delenda C. Lentiviral vectors: optimization of packaging, transduction and gene expression. J Gene Med 2004; 6 Suppl 1: S125-S138.
32. Newcomb EW, Lukyanov Y, Schnee T, Esencay M, Fischer I, Hong D, et al. The geldanamycin analogue 17-allylamino-17-demethoxygeldanamycin inhibits the growth of GL261 glioma cells in vitro and in vivo. Anticancer Drugs 2007; 18: 875-882.
33. Hannon GJ. RNA interference. Nature 2002; 418: 244-251.
34. Tuschl T, Borkhardt A. Small interfering RNAs: a revolutionary tool for the analysis of gene function and gene therapy. Mol Interv 2002; 2: 158-167.